By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Zealand Pharma A/S  

Smedeland 26 B

Glostrup    DK-2600  Denmark
Phone: 45-43-28-12-00 Fax: 45-43-28-12-12


Company News
Zealand Pharma  (ZEAL.CO) Presented Danegaptide As A Case Study On An Innovative Novel Peptide Therapeutic At The 9th Annual Peptide Therapeutics Symposium In The U.S. 10/29/2014 7:39:06 AM
Notice Of Zealand Pharma  (ZEAL.CO)'s Interim Report For H1 2014 And Related Conference Call 8/18/2014 7:02:26 AM
Zealand Pharma  (ZEAL.CO) Reports Increased Lyxumia® Royalty Revenue For H1 2014 And Informs Of Status Update As Provided By Sanofi 7/31/2014 9:17:34 AM
Zealand Pharma  (ZEAL.CO), Boehringer Ingelheim Corporation Strike $402 Million Peptide Pact 7/28/2014 9:06:40 AM
Zealand Pharma  (ZEAL.CO) Provides An Update On Activities Relating To Danegaptide For The Protection Of Cardiac Tissue Against Reperfusion Injuries 6/24/2014 9:05:23 AM
Zealand Pharma  (ZEAL.CO) Presented New Data On Two Novel Peptide Therapeutics From Its Preclinical Diabetes Pipeline At The American Diabetes Association 74th Scientific Sessions 6/17/2014 9:01:57 AM
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014 9:00:44 AM
Zealand Pharma  (ZEAL.CO)’s GLP-2 Analogue European Patent Rights Upheld By The European Patent Office Opposition Division 6/12/2014 8:24:50 AM
Zealand Pharma  (ZEAL.CO) Release: Presentation Of Several Zealand Peptide Therapeutics At The American Diabetes Association 74th Scientific Sessions 6/10/2014 9:49:38 AM
Zealand Pharma  (ZEAL.CO) To Present At Three Global Healthcare Investor Conferences In June 2014 5/23/2014 10:16:18 AM